Thisprospective studywas conductedfrom October 2015 to November 2019 at the National Cancer Institute of Egypt, evaluating the benefit of applying induction chemotherapy to the management of patients with locally advanced resectableoral tongue squamous cell carcinoma (SCCOT). Sixty-five patients aged 30-71 years with clinical T2-3N0-2M0 SCCOT were planned to receive at least 2 cycles of induction chemotherapy(IC) with docetaxel, cisplatin, and fluorouracil (TPF) protocol then according to their responses being followed by radical concurrent chemoradiation therapy in case of complete response (CR) otherwise surgery then adjuvant radiation therapy. Fifty-two patients received the planned protocol, the outcome was compared to another historical retrospectively matching group, including 52 adult patients who were offered upfront surgery +/- adjuvant radiation or chemoradiation therapy based on their pathological risks.54 (83.1%) patientsout of the 65 IC group had acceptableclinicalresponses, with 40% achieving CR.There wasa 94.2 % total response rate in the fifty-two patients who followed the planned protocol. After a median follow-up of 33 months, there was no significant statistical difference in OS (P=0.620) or DFS (P=0.407) compared to historical upfront surgery.CRin the IC group was associated with superior OS thannon-CR(P=0.031).And a better OS with post-inductionCCRT thanpost-inductionSurgery (P=0.068).Survival and recurrence rate for stage III & IVASCCOT after TPFinduction chemotherapy isnon-inferior to upfrontsurgery, witha higher rate of organ preservation.Additionally, CR is associated with better survival and could be used to predict patient outcomes.